Form 4: Crinetics Pharmaceuticals Officer Exercises, Sells Shares

Crinetics Pharmaceuticals' Chief Medical and Development Officer, Dana Pizzuti, exercised stock options and sold 5,000 shares of common stock under a pre-arranged trading plan.

Summary

• Dana Pizzuti, Chief Medical and Development Officer of Crinetics Pharmaceuticals, Inc. (CRNX), engaged in a transaction on September 2, 2025.
• Pizzuti exercised stock options to acquire 5,000 shares of common stock at an exercise price of $16.89 per share.
• Concurrently, Pizzuti sold 5,000 shares of common stock in open market transactions at a volume-weighted average sales price of $32.10 per share.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025.
• Following these transactions, Pizzuti directly beneficially owns 96,270 shares of common stock and 84,042 stock options.
• The range of sales prices for the common stock on the transaction date was $32.00 to $32.24 per share.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine insider transaction involving both an exercise of options and a sale of shares under a pre-arranged 10b5-1 trading plan, which is generally not indicative of a significant change in management's view of the company's prospects.

Positives

• The exercise of stock options indicates that the officer is realizing value from their compensation, with the exercise price significantly lower than the sale price, demonstrating a profit on the exercised shares.

Negatives

• The sale of shares by an insider, even under a pre-arranged plan, can sometimes be perceived as a reduction in direct exposure to the company's equity by a key executive.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing is a routine disclosure of an insider stock transaction and does not provide information directly related to broader industry trends or competitive landscape within the biotechnology or pharmaceutical sector.

Stakeholder Impact

• Shareholders: The transaction is a routine insider disclosure and is unlikely to have a significant direct impact on shareholders. The sale under a 10b5-1 plan suggests a pre-planned liquidity event rather than a discretionary decision based on new information.

Key Dates

Recommendation

A 'hold' recommendation is appropriate as this Form 4 filing details a routine insider transaction (exercise and sale) executed under a pre-arranged 10b5-1 trading plan. Such transactions are typically for personal financial planning and do not usually signal a change in the company's fundamental outlook or warrant a strong buy or sell recommendation based solely on this disclosure. Investors should consider broader company performance, industry trends, and other financial reports for investment decisions.

Keywords

Crinetics Pharmaceuticals, CRNX, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Rule 10b5-1 Plan, Dana Pizzuti, Chief Medical and Development Officer